CannTrust Investors Hazy After Secondary Offering
Marijuana producer CannTrustintends to price more than 36 million shares to result in a secondary offering valued up to roughly $230 million.
This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.
CannTrust Holdings Inc. (NYSE: CTST) shares dropped on Thursday after the firm announced the pricing of its secondary offering. The company intends to price its 36.36 million shares at $5.50 per share, with an overallotment option for an additional 5.45 million shares. At this price, the entire offering is valued up to roughly $230 million.
Out of the 36.36 million shares being sold, 30.90 million are being sold by the company, while 5.45 million are being sold by selling shareholders.
The underwriters for the offering are Merrill Lynch, Citigroup, Credit Suisse, RBC Capital Markets, Jefferies and Canaccord Genuity.
For some quick background: CannTrust is a federally regulated licensed producer of medical and recreational cannabis in Canada. Founded by pharmacists, CannTrust brings more than 40 years of pharmaceutical and health care experience to the medical cannabis industry and serves more than 69,000 medical patients with its dried, extract and capsule products.
[nativounit]
CannTrust intends to use the net proceeds of the offering for general corporate purposes, including cultivation and facility expansion, expanded outdoor growing, international expansion, enhanced extraction capacity, upgrades for GMP Certification and biosynthesis development.
Excluding Thursday’s move, CannTrust had outperformed the broad markets, with the stock up about 33.5% year to date.
Shares of CannTrust were last seen down about 12% at $5.66, in a post-IPO range of $4.76 to $10.17.
[recirclink id=545065]
[wallst_email_signup]
Contact [email protected] for any questions or corrections.
Chris Lange is a financial and geopolitical writer with more than a decade of experience covering a myriad of topics. He has published thousands of articles for 24/7 Wall St., with past coverage focused heavily on stocks, IPOs, healthcare, defense, global affairs, and technology.
His work has been quoted, or referenced by a number of outlets including Business Insider, USA Today, Yahoo Finance, MSN, The Motley Fool, and many other publications. A graduate of Southwestern University, he studied business with a focus on investments and has previous experience in banking and startups.
When not reading or writing the news, he is following his passion for Lacrosse, playing chess, or building solar projects with his dad.
